Dr. Chen is part of a distinguished group at Burrill consisting of professionals who are called upon to use their extensive academic training and international background to harness the vast potential in the biotech industry.  In his professional career, Dr. Chen has made numerous contributions in assessing technology, transferring discoveries into the clinic, raising venture investment and establishing strategic partnerships among pharmaceutical and biotech companies.  Dr. Chen's current merchant banking activities are spread out worldwide and include relationships in Australia, Canada, China, and the United Kingdom.  Previously Dr. Chen built talented scientific teams in immunology, genomics, virology, gene therapy and cell biology at Roche Diagnostics, Sentinel Biosciences, Progenesys, and SyStemix (a Novartis company). He played a key role in the IPO of the first biotech start-up that he joined, as well as the acquisition of SyStemix and Sentinel Biosciences by Novartis and Roche Diagnostics.  Dr. Chen studied at the University of Wisconsin-Madison and Stanford University.